What's next for psychedelics after MDMA rejection?
Science August 16, 2024 DOI: 10.1126/science.ads4470 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Psychedelic medicine Mental health treatments Pharmaceutical research Drug development Therapeutic compounds |
| Citations | 12 |
| Key points | Lykos's failure to gain FDA approval for a PTSD therapy may accelerate strategic shifts among its competitors in the psychedelic medicine field. |
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.
Citations in the library
Cited by 9
- Effects of 3,4-methylenedioxymethamphetamine on the gut microbiota and metabolites in the small intestine, cecum, and colon of male rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025
- Effects of Intravenous Ketamine on Posttraumatic Stress Disorder ( PTSD ): A Systematic Review Acta Psychiatrica Scandinavica December 1, 2025
- Psychedelics, OCD and Related Disorders: Setting methodological strategies for future studies Journal of Obsessive-Compulsive and Related Disorders March 19, 2025
- Psychedelic- and Substance-Assisted Therapies in Global Mental Health: Bridging Cultures, Evidence, and Access. Brain and Behavior February 1, 2026
- Dose-effect analysis of 6-APB ("Benzofury") on fear memory, motor behavior, and reward. Psychopharmacology July 14, 2026
and 4 more in the library